Floatz logo

Copper Cu 64 Anti-Cea Monoclonal Antibody M5A

Locally Advanced Rectal Carcinoma

City of Hope Medical Centermonoclonal_antibodyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

113 Active assets in the Locally Advanced Rectal Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Fudan University
Phase 2BBB
Capecitabine
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4BBB
Eloxatin
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB

View all 50 →

Same molecule, other indications

Copper Cu 64 Anti-Cea Monoclonal Antibody M5A is also rated in:

rectal cancerDormant
C
Indicative ·
39 / 100
View asset →
extrahepatic bile duct carcinomaDormant
D
Indicative ·
30 / 100
View asset →
gallbladder cancerDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →